Sample Size in the Planning and Interpretation of Clinical Trials

Abstract

An understanding of sample size determination is important in both planning and interpreting the results of clinical trials. A Type II error occurs when it is concluded that there is no difference between treatment groups, when in truth there is a difference. Such a false negative conclusion results from too few patients in a trial. In this review the principles of estimating sample size before a trial is commenced and evaluating the results of a negative completed trial are reviewed. Clinically relevant examples are used to illustrate these concepts.

Keywords

Sample size - Clinical trials

• References

• 1 Freiman J, Chalmers TC, Smith H, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. N Engl J Med 1978; 299: 690-694
• 2 Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med 1979; 301: 1410-1412
• 3 Sackett DL. Biases in analytic research. J Chronic Dis 1979; 32: 51-63
• 4 Gent M, Hirsh J. Definition of high risk/high response population for stroke in patients with transient ischemic attacks. Thromb Ilaemostas 1979; 41: 43-57
• 5 Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Controlled Clinical Trials 1981; 2: 93-113
• 6 Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. Wright; Boston: 1981. p 69-88
• 7 Salzman EW, Hirsh J. Prevention of venous thromboembolism. In: Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds.) Lippincott; Philadelphia: 1982. p 987-999
• 8 Turpie A GG, Levine MN, Hirsh J. et al A randomized controlled trial of a low molecular weight heparin (enoxaprin) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929
• 9 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245
• 10 Gouault-Heilmann M, Huet Y, Contant G, Payen D, Bloch G, Rapin M. Cardiopulmonary bypass with a low-molecuar weight heparin fraction. Lancet 1983; 2: 1374
• 11 Massonnet-Castel S, Pelissier E, Dreyfus G. et al Low-molecular weight heparin in extracorporal circulation. Lancet 1984; 2: 1182-1183
• 12 Salzman EW, Weinstein MJ, Weintraub RM. et al Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. N Engl J Med 1986; 314: 1402-1406
• 13 Colton T. Statistics in Medicine. Little Brown; Boston: 1974. p 151-183
• 14 Detsky AS, Sackett DL. When was a “negative” clinical trial big enough?. Archives Int Med 1985; 145: 709-712
• 15 Simon R. Confidence intervals for reporting results of clinical trials. Ann Int Med 1986; 105: 429-435
• 16 Bulpitt CJ. Confidence intervals. Lancet 1987; 1: 494-497
• 17 Fleis JL. Statistical Methods for Rates and Proportions. Wiley & Sons; New York: 1981. p 29-32
• 18 Gart JJ. The comparison of proportions: a review of significance tests, confidence intervals, and adjustments for stratification. Rev Intern Statist Inst 1971; 39: 148-169
• 19 Duke RJ, Bloch RF, Turpie A GG. et al Intravenous heparin for the prevention of stroke progression in acute partial stable stroke: A randomized controlled trial. Ann Int Med 1986; 105: 825-828
• 20 Hull R, Hirsh J, Jay R. et al Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med 1982; 307: 1676-1681
• 21 Levine MN, Hirsh J. Hemorrhagic complications of anticoagulant therapy. Semin Thrombos Haemost 1986; 12: 39-57
• 22 Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. John Wright Inc.; Boston: 1981. p 85
• 23 Dunnett CW, Gent M. Significance testing to establish equivalence between treatments. Biometrics 1977; 33: 593-602
• 24 McCarthy ST, Robertson D, Turner JJ, Hawkey CJ. Low dose heparin as a prophylaxis against deep vein thrombosis after acute stroke. Lancet 1977; 2: 800-801